Delving into the Latest Updates on 杭州泰格医药科技股份有限公司 with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

关联

1

项与杭州泰格医药科技股份有限公司相关的药物

VG-290131

靶点-

作用机制-

在研机构

杭州泰格医药科技股份有限公司

原研机构

浙江春禾医药科技有限公司

在研适应症-

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

36

项与杭州泰格医药科技股份有限公司相关的临床试验

NCT06666335

/ Not yet recruiting临床4期

A Prospective, Open-label, Single Arm, Multicenter, Post-authorization Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Colchicine-resistant Familial Mediterranean Fever (FMF)

The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with colchicine-resistand Familial Mediterranian Fever (FMF). The study consists of up to one month screening, to see if a patient is suitable to the study, 6 months of treatment with anakinra and one month safety follow up after last dose of anakinra. In total 3 patients, male and female from 2 years of age (minimum 10kg weight), will be enrolled to the study.

开始日期2025-04-01

申办/合作机构

Swedish Orphan Biovitrum AB

[+1]

NCT06581575

/ Active, not recruiting临床2期

A Phase 2, Randomized, Triple-Blinded, Active-Controlled Study to Assess the Safety and Immunogenicity of an Investigational Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects ≥ 50 Years of Age

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles).
Subjects will be randomized to receive either JCXH-105 or Shingrix.

开始日期2024-10-16

申办/合作机构

嘉晨西海（杭州）生物技术有限公司

[+1]

NCT06564194

/ Active, not recruiting临床1期

A Phase 1 Randomized, Double-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of JCXH-108, an mRNA-based Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Healthy Subjects ≥ 60 Years of Age and 18-45 Years of Age

The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases.
Participants will be randomized to receive either JCXH-108 or placebo.

开始日期2024-09-25

申办/合作机构

嘉晨西海（杭州）生物技术有限公司

[+1]

100 项与杭州泰格医药科技股份有限公司相关的临床结果

登录后查看更多信息

0 项与杭州泰格医药科技股份有限公司相关的专利（医药）

登录后查看更多信息

100 项与杭州泰格医药科技股份有限公司相关的药物交易

登录后查看更多信息

100 项与杭州泰格医药科技股份有限公司相关的转化医学

登录后查看更多信息